Cycle Group Holdings Limited (“Cycle”) is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; “Applied”), a clinical-stage biopharmaceutical company.

Cycle Group Holdings Limited（“Cycle”）欣然宣布，已完成对纳斯达克上市的临床阶段生物制药公司 Applied Therapeutics, Inc.（纳斯达克代码：APLT；“Applied”）的收购。

Applied’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available..

应用药物公司（Applied）的主要候选药物Govorestat是一种新型的中枢神经系统（CNS）渗透性醛糖还原酶抑制剂（ARI），用于治疗CNS罕见代谢疾病，包括经典半乳糖血症、夏科-马里-图斯病山梨醇脱氢酶缺乏症（CMT-SORD）以及磷酸甘露糖变位酶2先天性糖基化障碍（PMM2-CDG），目前尚无FDA批准的治疗方案可用。

“Cycle was founded with a commitment to support patients living with rare metabolic diseases. From our beginnings with NITYR®, we have grown to offer three therapies for this community. With Applied Therapeutics now a part of the Cycle group, we can look to expand further in this area. Our focus remains the same: to bring meaningful, reliable treatments to the patients and families who need them most.” says James Harrison, CEO of Cycle..

“Cycle 公司创立时便承诺支持那些生活在罕见代谢疾病中的患者。从我们最初的 NITYR® 开始，我们已经发展到为这一群体提供三种疗法。随着 Applied Therapeutics 现在成为 Cycle 集团的一部分，我们有望在这一领域进一步扩展。我们的重点依然不变：为最需要的患者和家庭带来有意义且可靠的治疗。” Cycle 首席执行官詹姆斯·哈里森说道。

The transaction is to be funded from cash on hand.

该交易将由手头现金资助。

For Cycle, Goodwin Procter LLP acted as legal counsel. For Applied, Aquilo Partners, L.P. provided a fairness opinion, and Ropes & Gray LLP acted as legal counsel.

对于Cycle，Goodwin Procter LLP担任法律顾问。对于Applied，Aquilo Partners, L.P.提供了公平意见书，Ropes & Gray LLP担任法律顾问。

©2026 Cycle Pharmaceuticals Ltd. All rights reserved. NITYR is a registered trademark of Cycle Pharmaceuticals Ltd in the United States.

©2026 Cycle Pharmaceuticals Ltd. 保留所有权利。NITYR 是 Cycle Pharmaceuticals Ltd 在美国的注册商标。

About Cycle Pharmaceuticals

关于Cycle制药公司

Cycle was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease community. Cycle focuses on rare genetic conditions in metabolic, immunology, urology, and oncology. In neurology, we focus on multiple sclerosis. Cycle is headquartered in Cambridge, UK and has offices in Detroit, Michigan, Boston, Massachusetts and High Point, North Carolina.

Cycle 于2012年成立，其唯一目标是为服务不足的罕见病群体提供药物治疗和产品支持。Cycle 专注于代谢、免疫学、泌尿学和肿瘤学中的罕见遗传疾病。在神经学领域，我们专注于多发性硬化症。Cycle 总部位于英国剑桥，在美国密歇根州底特律、马萨诸塞州波士顿以及北卡罗来纳州高点均设有办事处。

For more information, please visit www.cyclepharma.com and follow us on X, LinkedIn and Facebook..

有关更多信息，请访问 www.cyclepharma.com 并在 X、LinkedIn 和 Facebook 上关注我们。

Contacts

联系人

FOR FURTHER INFORMATION PLEASE CONTACT

欲了解更多信息，请联系

marketing@cyclepharma.com

marketing@cyclepharma.com

Cycle Pharmaceuticals Ltd

循环制药有限公司

Tel: +44 1223 354 118

电话：+44 1223 354 118

Source: businesswire.com

来源：businesswire.com